Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
We propose that the increase in circulating glucagon observed following genetic/pharmacological inactivation of glucagon signalling in mice and in people with type 2 diabetes reflects the removal of GLP-1(936)s glucagonostatic action
Gilbert, H.D
25 GLP-1 additionally exerts anorexigenic effects through the central nervous system, particularly within the hypothalamus and brainstem
It was first approved by the FDA in 2005
US$ 27.85
US$ 28.07
US$ 28.34
US$ 26.84
US$ 20.47
